GlassScriptPhysician profile
Biji Joseph
NPI 1437507217
$2,020.60
in general payments reported to CMS, 2019-2025
20 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.16 · 2022: $219 · 2023: $665 · 2024: $705 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,786.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $281.53 | 2022-2025 | |
| Edwards Lifesciences Corporation | $250.70 | 2023-2024 | The Edwards Sapien 3 Valve With Alterra Adaptive Prestent System |
| Amgen INC. | $158.89 | 2022-2025 | Repatha, Repatha |
| Irhythm Technologies, INC. | $153.49 | 2024 | Zio Monitor, Zio Xt Patch |
| Janssen Pharmaceuticals, INC | $148.82 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.66 | 2023-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $110.99 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $110.60 | 2021-2025 | Farxiga |
| Medtronic, INC. | $100.78 | 2025 | Corevalve Evolut R, Apollotm |
| E.R. Squibb & Sons, L.L.C. | $97.46 | 2022-2025 | Camzyos, Eliquis |
| Cardiva Medical, INC. | $96.00 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 5f Vcs |
| Scpharmaceuticals INC. | $74.22 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $70.40 | 2022-2023 | Optimizer |
| Merck Sharp & Dohme LLC | $54.94 | 2023-2024 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $53.99 | 2024 | Arcalyst |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $40.00 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.34 | 2023 | Lifevest |
| W. L. Gore & Associates, INC. | $31.13 | 2023-2024 | Gore Cardioform Septal Occluder |
| Actelion Pharmaceuticals US, INC. | $22.03 | 2024 | Opsumit |
| Novo Nordisk INC | $19.63 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biji Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.